Could a simple blood test catch pancreatic cancer before It's too late?

NCT ID NCT07700992

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This study is testing a new blood test that looks at tiny particles called exosomes and their microRNA content, analyzed by machine learning, to detect pancreatic cancer early. It involves 600 people at high risk due to family history or pancreatic cysts. The goal is to see if this non-invasive liquid biopsy can spot cancer sooner and monitor disease better than current imaging methods.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
A panel of circulating microRNA tested in cell-free and exosome-derived blood samples
What this could lead to
If successful, this could lead to a simple blood test that catches pancreatic cancer earlier, when it is more treatable, and helps monitor the disease without invasive procedures.
What could go wrong
This is an early-stage study focused on accuracy, not yet proven to improve survival. The test may not be sensitive or specific enough for widespread use, and results need validation in larger, diverse populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FAMILIAL PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • IRCCS San Raffaele Hospital

    RECRUITING

    Milan, MI, 20132, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.